Toward a third term of Health Japan 21 - implications from the rise in non-communicable disease burden and highly preventable risk factors.
Toward a third term of Health Japan 21 - implications from the rise in non-communicable disease burden and highly preventable risk factors.
复制标题
DOI：
10.1016/j.lanwpc.2021.100377
复制
发表时间：
2022-04
期刊：
影响因子：
--
通讯作者：
Inoue M
中科院分区：
文献类型：
--
作者：
Nomura S;Sakamoto H;Ghaznavi C;Inoue M
2000年，日本政府发起了名为“健康日本21”（HJ 21）的全国健康促进运动，这是一项为期13年的全国健康促进政策（2000-2012年），旨在预防和控制非传染性疾病（NCD）及其潜在风险因素。在2013年修订（2013-2023年）后，正在审查非传染性疾病目标和风险因素，并将讨论HJ 21第三个任期的新战略。本文利用2019年全球疾病负担研究的最新发现，强调了继续增加健康损失和可预防的代谢和行为风险因素的非传染性疾病。这些非传染性疾病和风险因素与新型冠状病毒病（COVID-19）导致的严重疾病和死亡风险增加有关。HJ 21的第三个任期将在当前COVID-19大流行等严重健康危机的持续威胁下制定，因此提供了一个重要的机会，以重新启动公共卫生工作，遏制日本日益增长的非传染性疾病负担。这篇文章可以作为制定HJ 21第三任期的路线图之一。
In 2000, the Japanese government launched the National Health Promotion Movement known as Health Japan 21 (HJ21), a 13-year national health promotion policy (2000–2012) aimed at preventing and controlling non-communicable diseases (NCDs) and their underlying risk factors. After the revision in 2013 (2013–2023), the target NCDs and risk factors are being reviewed and a new strategy for the third term of HJ21 is going to be discussed. Using the latest findings from the Global Burden of Disease Study 2019, this paper highlights NCDs that continue to increase health losses and preventable metabolic and behavioural risk factors. These NCDs and risk factors are associated with an increased risk of serious illness and death from the novel coronavirus disease (COVID-19). The third term of HJ21 will be formulated during the continuing threat of acute health crises like the current COVID-19 pandemic and thus offers an important opportunity to renew public health efforts to halt the growing burden of NCDs in Japan. This article may serve as one of the roadmaps for the formulation of the third term of HJ21.
登录
查看更多内容
DOI：
10.1016/s0140-6736(20)32332-1
发表时间：
2020-11-21
期刊：
Lancet (London, England)
影响因子：
--
作者：
Gencer B;Marston NA;Im K;Cannon CP;Sever P;Keech A;Braunwald E;Giugliano RP;Sabatine MS
通讯作者：
Sabatine MS
DOI：
10.1016/s0140-6736(21)00516-x
发表时间：
2021-03-13
期刊：
Lancet (London, England)
影响因子：
--
作者：
GBD 2019 Hearing Loss Collaborators
通讯作者：
GBD 2019 Hearing Loss Collaborators
影响因子：
5.2
作者：
Katanoda K;Jiang Y;Park S;Lim MK;Qiao YL;Inoue M
通讯作者：
Inoue M
影响因子：
168.9
作者：
Ikeda, Nayu;Saito, Eiko;Shibuya, Kenji
通讯作者：
Shibuya, Kenji
DOI：
10.1016/s0140-6736(16)30054-x
发表时间：
2016-04-02
期刊：
Lancet (London, England)
影响因子：
--
作者：
NCD Risk Factor Collaboration (NCD-RisC)
通讯作者：
NCD Risk Factor Collaboration (NCD-RisC)